IDEAS home Printed from https://ideas.repec.org/a/spr/stabio/v10y2018i2d10.1007_s12561-016-9178-4.html
   My bibliography  Save this article

Adaptive Biomarker Population Selection in Phase III Confirmatory Trials with Time-to-Event Endpoints

Author

Listed:
  • Xiaoyun Li

    (Merck & Co., Inc.)

  • Cong Chen

    (Merck & Co., Inc.)

  • Wen Li

    (Merck & Co., Inc.)

Abstract

A key component of modern drug development is to identify the patient population(s) that benefit most from the therapy. Subjects with different biomarker/genetic profiles may respond to a therapy differently. At the same time, data of populations with best efficacy may not be available due to lack of randomized data or biomarker assay when designing the phase III confirmatory trials. In this manuscript, we propose an adaptive design that performs biomarker-informed population selection at the interim analysis, so as to refine the population for primary hypothesis at the final analysis. Unlike most of the previous research work, where the same endpoint is used for interim population selection and final analysis, we propose to use a sensitive intermediate endpoint (whenever available) for population selection. Treatment effect of the intermediate endpoint is treated as a nuisance parameter to ensure type I error control. The use of a sensitive intermediate endpoint for biomarker population selection further improves study power. Simulations were conducted to evaluate the control of overall type I error, probabilities of population selection, and power.

Suggested Citation

  • Xiaoyun Li & Cong Chen & Wen Li, 2018. "Adaptive Biomarker Population Selection in Phase III Confirmatory Trials with Time-to-Event Endpoints," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 10(2), pages 324-341, August.
    • Handle: RePEc:spr:stabio:v:10:y:2018:i:2:d:10.1007_s12561-016-9178-4
    DOI: 10.1007/s12561-016-9178-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s12561-016-9178-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s12561-016-9178-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Tomasz Burzykowski & Geert Molenberghs & Marc Buyse & Helena Geys & Didier Renard, 2001. "Validation of surrogate end points in multiple randomized clinical trials with failure time end points," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 50(4), pages 405-422.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Erin E. Gabriel & Michael J. Daniels & M. Elizabeth Halloran, 2016. "Comparing biomarkers as trial level general surrogates," Biometrics, The International Biometric Society, vol. 72(4), pages 1046-1054, December.
    2. Casimir Ledoux Sofeu & Virginie Rondeau, 2020. "How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-25, January.
    3. Ariel Alonso & Helena Geys & Geert Molenberghs & Michael G. Kenward & Tony Vangeneugden, 2004. "Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach," Biometrics, The International Biometric Society, vol. 60(4), pages 845-853, December.
    4. Lindsay A. Renfro & Bradley P. Carlin & Daniel J. Sargent, 2012. "Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint," Biometrics, The International Biometric Society, vol. 68(1), pages 258-267, March.
    5. Arielle Anderer & Hamsa Bastani & John Silberholz, 2022. "Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?," Management Science, INFORMS, vol. 68(3), pages 1982-2002, March.
    6. Hirofumi Michimae & Takeshi Emura, 2022. "Bayesian ridge estimators based on copula-based joint prior distributions for regression coefficients," Computational Statistics, Springer, vol. 37(5), pages 2741-2769, November.
    7. Renfro, Lindsay A. & Shi, Qian & Xue, Yuan & Li, Junlong & Shang, Hongwei & Sargent, Daniel J., 2014. "Center-within-trial versus trial-level evaluation of surrogate endpoints," Computational Statistics & Data Analysis, Elsevier, vol. 78(C), pages 1-20.
    8. Debashis Ghosh, 2009. "On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm," Biometrics, The International Biometric Society, vol. 65(2), pages 521-529, June.
    9. Bo-Hong Wu & Hirofumi Michimae & Takeshi Emura, 2020. "Meta-analysis of individual patient data with semi-competing risks under the Weibull joint frailty–copula model," Computational Statistics, Springer, vol. 35(4), pages 1525-1552, December.
    10. Steffen Fieuws & Geert Verbeke, 2006. "Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles," Biometrics, The International Biometric Society, vol. 62(2), pages 424-431, June.
    11. Tomasz Burzykowski & Geert Molenberghs & Marc Buyse, 2004. "The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 167(1), pages 103-124, February.
    12. Debashis Ghosh, 2008. "Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data," Biometrics, The International Biometric Society, vol. 64(1), pages 149-156, March.
    13. Welz, Thilo & Viechtbauer, Wolfgang & Pauly, Markus, 2023. "Cluster-robust estimators for multivariate mixed-effects meta-regression," Computational Statistics & Data Analysis, Elsevier, vol. 179(C).
    14. Layla Parast & Tianxi Cai & Lu Tian, 2023. "Testing for heterogeneity in the utility of a surrogate marker," Biometrics, The International Biometric Society, vol. 79(2), pages 799-810, June.
    15. Shi, Qian & Renfro, Lindsay A. & Bot, Brian M. & Burzykowski, Tomasz & Buyse, Marc & Sargent, Daniel J., 2011. "Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials," Computational Statistics & Data Analysis, Elsevier, vol. 55(9), pages 2748-2757, September.
    16. Debashis Ghosh & Jeremy M. G. Taylor & Daniel J. Sargent, 2012. "Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling," Biometrics, The International Biometric Society, vol. 68(1), pages 226-232, March.
    17. Ghosh Debashis, 2008. "On the Plackett Distribution with Bivariate Censored Data," The International Journal of Biostatistics, De Gruyter, vol. 4(1), pages 1-22, May.
    18. Rui Zhuang & Ying Qing Chen, 2020. "Measuring Surrogacy in Clinical Research," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 12(3), pages 295-323, December.
    19. Layla Parast & Lu Tian & Tianxi Cai, 2020. "Assessing the value of a censored surrogate outcome," Lifetime Data Analysis: An International Journal Devoted to Statistical Methods and Applications for Time-to-Event Data, Springer, vol. 26(2), pages 245-265, April.
    20. Lorna Wheaton & Anastasios Papanikos & Anne Thomas & Sylwia Bujkiewicz, 2023. "Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation," Medical Decision Making, , vol. 43(5), pages 539-552, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:stabio:v:10:y:2018:i:2:d:10.1007_s12561-016-9178-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.